Suppr超能文献

膜联蛋白A2:作为与癌症转移及癌症微环境中耐药性相关的治疗靶点的可行性。

Annexin A2: the feasibility of being a therapeutic target associated with cancer metastasis and drug resistance in cancer microenvironment.

作者信息

Weijie Song

机构信息

Laboratory Animal Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.

Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.

出版信息

Discov Oncol. 2024 Dec 18;15(1):783. doi: 10.1007/s12672-024-01693-8.

Abstract

At present, there is still a lack of effective treatment strategies for cancer metastasis and drug resistance, so finding effective biomarkers is particularly important. AnnexinA2 (ANXA2), a vital membrane protein, critically influences cancer progression, tumor invasion, and tumor microenvironment modulation. To assess the possible application of ANXA2 as a therapeutic target against cancer cell metastasis and drug resistance to chemotherapeutic drugs in the tumor microenvironment, we elucidated the functionality of ANXA2 in stromal cells, angiogenic vascular cells, and infiltrated immune cells that mediate metastasis and drug resistance, as well as its potential as a therapeutic target. ANXA2 shows a high expression level in many tissues, and its expression level is even higher in several tumors and their microenvironments. ANXA2 is a crucial regulator of many factors and may serve as a target against drug-resistant cancers.

摘要

目前,对于癌症转移和耐药性仍缺乏有效的治疗策略,因此寻找有效的生物标志物尤为重要。膜联蛋白A2(ANXA2)是一种重要的膜蛋白,对癌症进展、肿瘤侵袭和肿瘤微环境调节具有关键影响。为了评估ANXA2作为针对肿瘤微环境中癌细胞转移和对化疗药物耐药性的治疗靶点的可能应用,我们阐明了ANXA2在介导转移和耐药性的基质细胞、血管生成血管细胞和浸润免疫细胞中的功能,以及其作为治疗靶点的潜力。ANXA2在许多组织中呈现高表达水平,在一些肿瘤及其微环境中的表达水平甚至更高。ANXA2是许多因子的关键调节因子,可能成为抗耐药性癌症的靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e696/11655786/4c5658a3e8ea/12672_2024_1693_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验